Pulmonary valve sarcoma in patient with coronavirus disease of 2019 (COVID-19), mimicking pulmonary thromboembolism, a very rare case

Rozita Jalalian MD1  |  Javad Sadraee MD1  |  Soheil Azizi MD1  |  Babak Bagheri MD1  |  Mohammadreza Iranian MD2

1 Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2 Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Correspondence
Rozita Jalalian, Associate Professor of Cardiology, FECAVI, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran. Email: rozitajalalian@yahoo.com

Abstract
Pulmonary artery and pulmonary valve sarcoma are malignant and very rare vascular tumors with aggressive clinical course and very poor outcomes. Patients affected by coronavirus disease of 2019 (COVID-19) are at a higher risk for thromboembolism complication. We describe a young woman with a history of coronavirus pneumonia and progressive dyspnea, hemodynamic disturbance, edema with initial evaluation, and clinical diagnosis of pulmonary thromboembolism. But further imaging study and pathology demonstrated giant sarcoma of pulmonary valve, obstructing pulmonary valve and extending to right ventricular outflow tract and main of pulmonary artery.

KEYWORDS
Covid-19, sarcoma, thromboembolism

1 INTRODUCTION

Pulmonary artery sarcomas (PASs) are the most common primary tumors of the pulmonary artery (PA). PASs are malignant and rare tumor and predominantly presented among patients from their third to seventh decade. Women are involved twice as often as men. The most common clinical manifestation of PASs is dyspnea followed by chest pain, cough, and hemoptysis. Systematic symptoms of PASs are less rare and they include weight loss, syncope, and fever. The presence of these symptoms often causes misdiagnosis of pulmonary thromboembolism (PTE).1-3

2 CASE REPORT

A 40-year-old woman presented at the emergency department because of progressive dyspnea, orthopnea, edema, weakness. She has involved with COVID-19 about 2 months ago according to polymerase chain reaction (PCR) and chest computed tomography (CT). At the same time, she suffered from fever, cough, and dyspnea and she was admitted to another hospital for 10 days due to hypoxemia. She was treated with corticosteroids and supportive therapies and discharged after improving her general condition, but she did not completely recover from respiratory symptoms in spite of adequate treatment. Discharge summary of the previous hospitalization did not mention any previous cardiovascular diseases. In admission time in our hospital, she has respiratory distress, tachycardia, tachypnea, edema, cyanosis and coldness of extremity and systemic hypotension (Blood Pressure: 90/65 mm Hg), O2 saturation in air room was 86% and with noninvasive O2 therapy increased to 89%.

Electrocardiogram (ECG) showed sinus tachycardia, right axis deviation, and right ventricle (RV) strain pattern (Figure 1). Chest X-ray showed significant cardiomegaly, RV enlargement, and prominent main of PA and left PA without evidence of pulmonary venous congestion (Figure 2). Spiral chest CT demonstrated evidence of previous COVID-19, cardiomegaly, and large size pericardial effusion (Figure 3).

Transthoracic echocardiography (TTE) showed severe RV enlargement with severe systolic dysfunction except RV apex that seems to have preserved motion and function before surgery (McConnell’s sign), right atrial (RA) enlargement, and abnormal interventricular septal motion. D-shaped appearance of interventricular septum in parasternal short axis (PSAX) view with mid systolic flattening, representing
FIGURE 1  Electrocardiogram. Electrocardiogram showed sinus tachycardia, right axis deviation and right ventricle strain pattern (qR in V1 and T inversion V1-V6).

FIGURE 2  Chest X-ray. Chest X-ray showed significant cardiomegaly, RV enlargement, and prominent main of PA and left PA without evidence of pulmonary venous congestion.

Severe RV pressure overload and signs of severely increased RV afterload pattern. In PSAX view, very large size nonhomogeneous solid mobile mass is seen in distal right ventricular outflow tract (RVOT) extended to main PA and has attachment to pulmonary valve (PV). The PV obstruction was severe and blood flow to main PA was reduced. Left and right PA and pulmonary bifurcation were evaluated, which were spared without any mass. Color doppler study of tricuspid valve (TV) inflow showed severe tricuspid regurgitation (TR) and hemodynamic study with continuous doppler wave in apical four-chamber view demonstrated TR peak velocity of 4.4 m/sec (TR peak gradient: 77 mm Hg). IVC was severely enlarged (2/75 cm diameter) without respiratory collapse. Therefore, hemodynamic study estimated RA pressure about 20 mm Hg, more compatible with chronic course of disease and indicating of more gradual increasing of RV pressure rather than acute event. Massive pericardial effusion was seen more localized in posterolateral of left ventricle (LV) (maximum diameter: more than 3 cm). There was significant respiratory variation in Doppler study of mitral valve (MV) and TV diastolic inflow velocity more than 30% (Figure 4).

In laboratory data, d-dimer was increased about 4000 µg/L and pro-brain natriuretic peptide (pro-BNP) 12 500 ng/day.

According to previous history of the COVID-19, ECG manifestation, echocardiography, chest X-ray, spiral chest CT, laboratory data and abnormal hemodynamic condition, massive sub-acute PTE was highly suggested. Due to our patient hemodynamic disturbance, massive pericardial effusion and giant mass, emergent cardiac consultation with cardiovascular surgical team for surgical resection was done, and the patient was taken to operating room.
FIGURE 3  Spiral chest computed tomography (CT). Chest CT showed evidence of previous COVID-19 involvement with ground glass appearance and air trapping in both lungs and also cardiomegaly.

FIGURE 4  Transthoracic echocardiography (TTE) before surgery. TTE showed severe RV enlargement with severe systolic dysfunction except RV apex that seems to have preserved motion and function before surgery (McConnell’s sign), right atrial (RA) enlargement, abnormal interventricular septal motion, severe TR, enlargement of IVC size, massive pericardial effusion, and mobile mass in distal right ventricular outflow tract (RVOT) extended to main PA and has attachment to pulmonary valve (PV).
Thoracotomy was done and unexpectedly, out of previous suspicious, our surgeon encountered with large size tumoral solid mass with firm texture that was attached to right leaflet of PV and protruded to main PA and RVOT, which appearance was highly suggestive for sarcoma rather thrombosis. Therefore, mass completely was resected and because of tumoral involvement, right leaflet of PV removed (Figure 5). Reevaluation for residual masses in other parts was done with intraoperative echocardiography. TEE confirmed there was not any other masses in PA. Severe pulmonary insufficiency (PI) was seen after removal of right leaflet of PV. Staged operation for reconstruction of RVOT with conduit PV was postponed after preparing the result of tumor pathology and probably need for adjuvant chemotherapy. Patient had stable hemodynamic in ICU, intubated easily, and discharged after 7 days without any cardiac event.

TTE was performed before discharge of the patient. RV and RA were severely enlarged. RV systolic function was severely impaired and severe TR and severe PI was seen. No residual mass was seen in RVOT, PV, PA, and main of PA. Continuous doppler wave study showed peak TR velocity 4 m/sec and short pressure half time (PHT: 24 msec) and in 2D study evidence of increased RV after load pattern was permanent. IVC plethora and engorgement without respiratory collapse was seen (Figure 6).

Pulmonary CT angiography was done before discharge that any mass or thrombus in pulmonary vasculature was not seen. In addition, abdominopelvic and brain CT for further evaluation were performed, which were not abnormal.

Histopathological examination of resected mass showed malignant mesenchymal neoplasm composed of sheets and individual tumoral cells embedded in a desmoplastic and collagenized stroma compatible with undifferentiated pleomorphic sarcoma (Figure 7).

The patient referred to oncologist for chemotherapy. Just the day before initiation of chemotherapy, TTE was done and recurrence of tumoral mass (1.5*1.5 cm) was seen in distal part of RVOT just beneath PV. Patient admitted in hospital for receiving chemotherapy. Unfortunately, after one course of chemotherapy, patient was died in hospital with cardiogenic shock because of severe right-sided heart failure.

3 | COMMENT

Primary cardiac sarcoma are rare tumors and sarcoma of PV are very rare.4 Initial manifestation of these tumors usually consist of non-specific symptoms of cardiopulmonary disease such as cough, dyspnea, chest pain, infrequently hemoptysis, pneumothorax, and tamponade in cases with invasion to pericardium, mediastina, or lung parenchyma.2–5 PA sarcoma can mimic clinical and paraclinical findings of PTE and cause difficulties in early diagnosis and management. Some case reports representing misdiagnosis of PA sarcoma with PTE in early evaluating and for this reason the patients underwent thrombolytic therapies without any improvement and subsequent evaluations demonstrated malignant tumor of pulmonary artery.1,6,7

Chest CT scan can help differentiate PA sarcoma from PTE by low-attenuation filling defect occupying the entire luminal diameter of the main or the proximal PA, expansion of any segment of the PA, and extraluminal extension of the tumor. These image features to be suggestive of PA sarcoma.9 Although MRI and FDG/PET CT can distinguish PASs from PTE,9,10 the only method to definitely differentiate diagnosis between PASs and PTE is tissue diagnosis.3 Other characteristics, such as the absence of risk factors for deep vein thrombosis and high erythrocytes sedimentation rate, should raise the suspicion of a process other than PTE.1

Surgery is the most effective treatment of PA sarcoma.1,7 Chemotherapy and radiotherapy are used and may provide longer survival, especially in patient with metastasis and incomplete resection. Endovascular stenting remains as palliative therapy for inoperable patient with obstructing tumors. Most cases of pulmonary sarcomas
were diagnosed late in course of diseases and these made difficulties in surgical resection. Some reports shown that early diagnosis and surgical resection may provide longer survival.4–7

Overall, PA sarcoma are very poor prognosis tumor because of late diagnosis and average of survival among reported case series were between 1.5 and 12 months.5,11 Among patients reported to have longer survival, RV function was preserved and did not mention significant increased PA pressure.5 Our patients had severe RV dysfunction in presentation and remaining of PA pressure severely high even after total resection of giant tumoral mass and in absence of any other
mass or thrombosis in pulmonary arteries in pulmonary CT angiography after operation. This can be due to microvascular disease. Pulmonary tumor microvascular disease includes both pulmonary tumor microembolism and pulmonary tumor thrombotic microangiopathy. These two conditions are likely to be a disease spectrum. Tumor emboli are frequently reported in autopsy specimens, and may even be asymptomatic. When PH does develop, progressive and fatal right ventricular failure ensues.12

Patients with COVID-19 pneumonia and high D dimer value has higher prevalence PTE and myocarditis.13–16 Prior infection with COVID-19 pneumonia in our case maybe the other causes of RV failure and also masquerading sarcoma.

On the other hand, RV dysfunction due to cardiotoxicity of chemotherapy may considered as the other mechanism for progression of RV failure in our patient. Chemotherapy could induce impairment of RV structure, function, and mechanistic.17,18

Our case report emphasizes that PASs should always be included in the differential diagnosis of PTE especially if symptoms progress despite anticoagulation therapy (or any risk factor for deep vein thrombosis is not present). However, our patient underwent surgery immediately due to impaired hemodynamic and was diagnosed early compared to the time of hospitalization.

**ORCID**

Rozita Jalalian MD https://orcid.org/0000-0001-9721-4950

**REFERENCES**

1. Toporcer T, Martinček M, Mistriková L, Sabel F. Primary pulmonary valve sarcoma involving pulmonary artery and right ventricular outflow tract. Cor et Vasa. 2015;57(5):e371-e376.
2. Kanjanauthai S, Kanluen T, Ray C. Pulmonary artery sarcoma masquerading as saddle pulmonary embolism. Heart Lung Circ. 2008;17:417-419.
3. Levy E, Korach A, Amir G, et al. Undifferentiated sarcoma of the pulmonary artery mimicking pulmonary thromboembolic disease. Heart Lung Circ. 2006;15:62-63.
4. Huo L, Moran CA, Fuller GN, Gladish G, Suster S. Pulmonary artery sarcoma: a clinicopathologic and immunohistochemical study of 12 cases. Am J Clin Pathol. 2006;125(3):419-424.
5. Morreau SP, Haydock DA. Prolonged survival of pulmonary artery sarcoma after aggressive surgical resection. Ann Thorac Surg. 2017;103(1):e21-e23.
6. Mahajan A, Rekhi B, Laskar S, Bajpai J, Jayasree L, Thakur MH. Primary pulmonary artery sarcoma masquerading as pulmonary thromboembolism: a rare diagnosis unveiled. Clin Sarcoma Res. 2017:7:13.
7. Kim JB, Kim SH, Lim SY, et al. Primary angiosarcoma of the pulmonary trunk mimicking pulmonary thromboembolism. Echocardiography. 2010;27(2):E23-6.
8. Yi CA, Lee KS, Choe YH, et al. Computed tomography in pulmonary artery sarcoma: distinguishing features from pulmonary embolic disease. J Computer Assist Tomogr. 2004;28:34-39.
9. Girard N, Triby-Moreau C, Benabidallah S, et al. Pulmonary artery sarcoma, a paradigm of orphan thoracic oncology. Presse Med. 2009;38:1167-1170.
10. Ito K, Kubota K, Morooka M, et al. Diagnostic usefulness of 18F-FDG PET/CT in the differentiation of pulmonary artery sarcoma and pulmonary embolism. Ann Nucl Med. 2009;23:671-676.
11. Said SM, Sundt TM 3rd, Garces YI, Wigle DA. 5-year survival after multiple repeat metastasectomy for pulmonary artery angiosarcoma. Ann Thorac Surg. 2011;91(4):e4951.
12. Price LC, Seckl MJ, Dorfmüller P, Wort SJ. Pulmonary arterial hypertension. Eur Respir Rev. 2019;28:180065.
13. Alonso-Fernández A, Toledo-Pons N, Cosio BG, et al. Prevalence of pulmonary embolism in patients with COVID-19 pneumonia and high D-dimer values: a prospective study. PloS One. 2020;15(8):e0238216.
14. Basso C, Leone O, Rizzo S, et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur Heart J. 2020;41(39):3827-3835.
15. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098.
16. Park JF, Banerjee S, Umar S. In the eye of the storm: the right ventricle in COVID-19. Pulmonary Circulation. 2020;10(3):1-7.
17. Jahangir E, Harinstein ME, Murthy VL, et al. The forgotten right ventricle in cardio-oncology. J Nucl Cardiol. 2020;27:2164-2166.
18. Tadic M, Cuspidi C, Herling D, Venneri L, Danylenko O. The influence of chemotherapy on the right ventricle: did we forget something?. Clin Cardiol. 2017;40(7):437-443. Epub 2017 Feb 13.

How to cite this article: Jalalian R, Sadraee J, Azizi S, Bagheri B, Iranian M. Pulmonary valve sarcoma in patient with coronavirus disease of 2019 (COVID-19), mimicking pulmonary thromboembolism, a very rare case. Echocardiography. 2021;38:1959–1965. https://doi.org/10.1111/echo.15213